Form 4 for ADPT Adaptive Biotechnologies Corp
Accepted 2025-02-18 00:00:00 ET · period of report 2025-02-13 · accession 0001062993-25-002744 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-02-18 | 2025-02-13+ | ADPT | ROBINS CHAD M | CEO, COB, Dir | M - OptEx | $6.32 | +470.4K | 2.74M | +21% | +$2.97M |
| DM | 2025-02-18 | 2025-02-13+ | ADPT | ROBINS CHAD M | CEO, COB, Dir | S - Sale+OE | $8.47 | -470.4K | 2.58M | -15% | -$3.99M |
| DM | 2025-02-18 | 2025-02-13+ | ADPT | ROBINS CHAD M | CEO, COB, Dir | M - OptEx | $0.00 | -470.4K | 285.2K | -62% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-13 | M | A | 100,287 | $6.32 | 2,676,988 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-13 | S | D | 100,287 | $8.44 | 2,576,701 | D | — | — | (F2) The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.56, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| 3 | Common | Common Stock | 2025-02-18 | S | D | 211,160 | $8.50 | 2,576,701 | D | — | — | (F4) The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| 4 | Common | Common Stock | 2025-02-14 | S | D | 158,921 | $8.46 | 2,576,701 | D | — | — | (F3) The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.69, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| 5 | Common | Common Stock | 2025-02-18 | M | A | 211,160 | $6.32 | 2,787,861 | D | — | — | |
| 6 | Common | Common Stock | 2025-02-14 | M | A | 158,921 | $6.32 | 2,735,622 | D | — | — | |
| 7 | Derivative | Stock Option (right to buy) | 2025-02-14 | M | D | 158,921 | $0.00 | 496,347 | D | $6.32 · — to 2025-06-09 | 158,921 Common Stock | (F5) The option is fully vested and exercisable. |
| 8 | Derivative | Stock Option (right to buy) | 2025-02-13 | M | D | 100,287 | $0.00 | 655,268 | D | $6.32 · — to 2025-06-09 | 100,287 Common Stock | (F5) The option is fully vested and exercisable. |
| 9 | Derivative | Stock Option (right to buy) | 2025-02-18 | M | D | 211,160 | $0.00 | 285,187 | D | $6.32 · — to 2025-06-09 | 211,160 Common Stock | (F5) The option is fully vested and exercisable. |